Life in the crypt: A role for glucagon-like peptide-2?

Molecular and Cellular Endocrinology

Volumn 288, Issue 1-2, 2008, Pages 63-70

  Rowland, Katherine J ^a   Brubaker, Patricia L ^a  

^a UNIVERSITY OF TORONTO   (Canada)

Author keywords

Crypt; GLP 2; Proliferation; Small intestine; Stem cell

Indexed keywords

BETA CATENIN; BONE MORPHOGENETIC PROTEIN; GLUCAGON LIKE PEPTIDE 1; GLUCAGON LIKE PEPTIDE 2; LITHIUM CHLORIDE; PROTEIN MUSASHI 1; REGULATOR PROTEIN; SMAD4 PROTEIN; SOMATOMEDIN C; WNT PROTEIN;

ARTICLE; CELL FUNCTION; CELL GROWTH; CELL PROLIFERATION; CELL STRUCTURE; CELL SURVIVAL; CRYPT CELL; DRUG MECHANISM; HOMEOSTASIS; HUMAN; INTESTINE CELL; INTESTINE EPITHELIUM; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN INTERACTION; PROTEIN SECRETION; SIGNAL TRANSDUCTION; SMALL INTESTINE; STEM CELL;

ANIMALS; GLUCAGON-LIKE PEPTIDE 2; HUMANS; INTESTINES; SIGNAL TRANSDUCTION;

EID: 44649147640     PISSN: 03037207     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.mce.2008.02.014     Document Type: Article

References (120)

1. Alison M.R., Poulsom R., Brittan M., Schier S., Burkert J., and Wright N.A. Isolation of gut SP cells does not automatically enrich for stem cells. Gastroenterology 130 (2006) 1012-1013 (author reply 1013-1014)
2. Anini Y., Hansotia T., and Brubaker P.L. Muscarinic receptors control postprandial release of glucagon-like peptide-1: in vivo and in vitro studies in rats. Endocrinology 143 (2002) 2420-2426
3. Anini Y., Izzo A., Oudit G.Y., Backx P.H., and Brubaker P.L. Role of phosphatidylinositol-3 kinase-gamma in the actions of glucagon-like peptide-2 on the murine small intestine. Am. J. Physiol. Endocrinol. Metab. 292 (2007) E1599-E1606
4. Bach S.P., Renehan A.G., and Potten C.S. Stem cells: the intestinal stem cell as a paradigm. Carcinogenesis 21 (2000) 469-476
5. Baregamian N., Song J., Jeschke M.G., Evers B.M., and Chung D.H. IGF-1 protects intestinal epithelial cells from oxidative stress-induced apoptosis. J. Surg. Res. 136 (2006) 31-37
6. Bastide P., Darido C., Pannequin J., Kist R., Robine S., Marty-Double C., Bibeau F., Scherer G., Joubert D., Hollande F., Blache P., and Jay P. Sox9 regulates cell proliferation and is required for Paneth cell differentiation in the intestinal epithelium. J. Cell Biol. 178 (2007) 635-648
7. Batlle E., Henderson J.T., Beghtel H., van den Born M.M., Sancho E., Huls G., Meeldijk J., Robertson J., van de Wetering M., Pawson T., and Clevers H. Beta-catenin and TCF mediate cell positioning in the intestinal epithelium by controlling the expression of EphB/ephrinB. Cell 111 (2002) 251-263
8. Behrens J. Control of beta-catenin signaling in tumor development. Ann. N.Y. Acad. Sci. 910, (2000) 21-33 discussion 33-25
9. Benjamin M.A., McKay D.M., Yang P.C., Cameron H., and Perdue M.H. Glucagon-like peptide-2 enhances intestinal epithelial barrier function of both transcellular and paracellular pathways in the mouse. Gut 47 (2000) 112-119
10. Bjerknes M., and Cheng H. Clonal analysis of mouse intestinal epithelial progenitors. Gastroenterology 116 (1999) 7-14
11. Bjerknes M., and Cheng H. Modulation of specific intestinal epithelial progenitors by enteric neurons. Proc. Natl. Acad. Sci. U.S.A. 98 (2001) 12497-12502
12. Blache P., van de Wetering M., Duluc I., Domon C., Berta P., Freund J.N., Clevers H., and Jay P. SOX9 is an intestine crypt transcription factor, is regulated by the Wnt pathway, and represses the CDX2 and MUC2 genes. J. Cell Biol. 166 (2004) 37-47
13. Booth C., Booth D., Williamson S., Demchyshyn L.L., and Potten C.S. Teduglutide ([Gly2]GLP-2) protects small intestinal stem cells from radiation damage. Cell Prolif. 37 (2004) 385-400
14. Boushey R.P., Yusta B., and Drucker D.J. Glucagon-like peptide 2 decreases mortality and reduces the severity of indomethacin-induced murine enteritis. Am. J. Physiol. 277 (1999) E937-E947
15. Boushey R.P., Yusta B., and Drucker D.J. Glucagon-like peptide (GLP)-2 reduces chemotherapy-associated mortality and enhances cell survival in cells expressing a transfected GLP-2 receptor. Cancer Res. 61 (2001) 687-693
16. Brittan M., and Wright N.A. Stem cell in gastrointestinal structure and neoplastic development. Gut 53 (2004) 899-910
17. Brubaker P.L., Izzo A., Hill M., and Drucker D.J. Intestinal function in mice with small bowel growth induced by glucagon-like peptide-2. Am. J. Physiol. 272 (1997) E1050-E1058
18. Bulut K., Pennartz C., Felderbauer P., Meier J.J., Banasch M., Bulut D., Schmitz F., Schmidt W.E., and Hoffmann P. Glucagon like peptide-2 induces intestinal restitution through VEGF release from subepithelial myofibroblasts. Eur. J. Pharmacol. 578 (2008) 279-285
19. Burrin D.G., Stoll B., Guan X., Cui L., Chang X., and Hadsell D. GLP-2 rapidly activates divergent intracellular signaling pathways involved in intestinal cell survival and proliferation in neonatal piglets. Am. J. Physiol. Endocrinol. Metab. 292 (2007) E281-E291
20. Burrin D.G., Stoll B., Jiang R., Chang X., Hartmann B., Holst J.J., Greeley Jr. G.H., and Reeds P.J. Minimal enteral nutrient requirements for intestinal growth in neonatal piglets: how much is enough?. Am. J. Clin. Nutr. 71 (2000) 1603-1610
21. Burrin D.G., Stoll B., Jiang R., Petersen Y., Elnif J., Buddington R.K., Schmidt M., Holst J.J., Hartmann B., and Sangild P.T. GLP-2 stimulates intestinal growth in premature TPN-fed pigs by suppressing proteolysis and apoptosis. Am. J. Physiol. Gastrointest. Liver Physiol. 279 (2000) G1249-G1256
22. Chance W.T., Foley-Nelson T., Thomas I., and Balasubramaniam A. Prevention of parenteral nutrition-induced gut hypoplasia by coinfusion of glucagon-like peptide-2. Am. J. Physiol. 273 (1997) G559-G563
23. Cheeseman C.I. Upregulation of SGLT-1 transport activity in rat jejunum induced by GLP-2 infusion in vivo. Am. J. Physiol. Regul. Integr. Comp. Physiol. 273 (1997) R1965-R1971
24. Chen J., Wu A., Sun H., Drakas R., Garofalo C., Cascio S., Surmacz E., and Baserga R. Functional significance of type 1 insulin-like growth factor-mediated nuclear translocation of the insulin receptor substrate-1 and beta-catenin. J. Biol. Chem. 280 (2005) 29912-29920
25. Cheng H., and Leblond C.P. Origin, differentiation and renewal of the four main epithelial cell types in the mouse small intestine V. Unitarian Theory of the origin of the four epithelial cell types. Am. J. Anat. 141 (1974) 537-561
26. Cosentino L., Shaver-Walker P., and Heddle J.A. The relationships among stem cells, crypts, and villi in the small intestine of mice as determined by mutation tagging. Dev. Dynam. 207 (1996) 420-428
27. Crosnier C., Stamataki D., and Lewis J. Organizing cell renewal in the intestine: stem cells, signals and combinatorial control. Nat. Rev. Genet. 7 (2006) 349-359
28. Dahly E.M., Gillingham M.B., Guo Z., Murali S.G., Nelson D.W., Holst J.J., and Ney D.M. Role of luminal nutrients and endogenous GLP-2 in intestinal adaptation to mid-small bowel resection. Am. J. Physiol. Gastrointest. Liver Physiol. 284 (2003) G670-G682
29. Dekaney C.M., Rodriguez J.M., Graul M.C., and Henning S.J. Isolation and characterization of a putative intestinal stem cell fraction from mouse jejunum. Gastroenterology 129 (2005) 1567-1580
30. Dhanvantari S., Seidah N.G., and Brubaker P.L. Role of prohormone convertases in the tissue-specific processing of proglucagon. Mol. Endocrinol. 10 (1996) 342-355
31. Ding L.A., and Li J.S. Gut in diseases: physiological elements and their clinical significance. World J. Gastroenterol. 9 (2003) 2385-2389
32. Drucker D.J., Erlich P., Asa S.L., and Brubaker P.L. Induction of intestinal epithelial proliferation by glucagon-like peptide 2. Proc. Natl. Acad. Sci. U.S.A. 93 (1996) 7911-7916
33. Drucker D.J., DeForest L., and Brubaker P.L. Intestinal response to growth factors administered alone or in combination with human [Gly2]glucagon-like peptide 2. Am. J. Physiol. 273 (1997) G1252-G1262
34. Drucker D.J., Shi Q., Crivici A., Sumner-Smith M., Tavares W., Hill M., DeForest L., Cooper S., and Brubaker P.L. Regulation of the biological activity of glucagon-like peptide 2 in vivo by dipeptidyl peptidase IV. Nat. Biotechnol. 15 (1997) 673-677
35. Drucker D.J., Yusta B., Boushey R.P., DeForest L., and Brubaker P.L. Human [Gly2]GLP-2 reduces the severity of colonic injury in a murine model of experimental colitis. Am. J. Physiol. 276 (1999) G79-G91
36. Dubé P.E., Forse C.L., Bahrami J., and Brubaker P.L. The essential role of insulin-like growth factor-1 in the intestinal tropic effects of glucagon-like peptide-2 in mice. Gastroenterology 131 (2006) 589-605
37. Dubé P.E., Rowland K.J., and Brubaker P.L. Glucagon-like peptide-2 activates beta-catenin signaling in the mouse intestinal crypt: role of insulin-like growth factor-1. Endocrinology 149 (2008) 291-301
38. Fodde R., Edelmann W., Yang K., van Leeuwen C., Carlson C., Renault B., Breukel C., Alt E., Lipkin M., Khan P.M., and Kucherlapati R. A targeted chain-termination mutation in the mouse Apc gene results in multiple intestinal tumors. Proc. Natl. Acad. Sci. U.S.A. 91 (1994) 8969-8973
39. Fodde R., Smits R., and Clevers H. APC, signal transduction and genetic instability in colorectal cancer. Nat. Rev. Cancer 1 (2001) 55-67
40. Gleeson M.H., Bloom S.R., Polak J.M., Henry K., and Dowling R.H. Endocrine tumour in kidney affecting small bowel structure, motility, and absorptive function. Gut 12 (1971) 773-782
41. Guan X., Karpen H.E., Stephens J., Bukowski J.T., Niu S., Zhang G., Stoll B., Finegold M.J., Holst J.J., Hadsell D., Nichols B.L., and Burrin D.G. GLP-2 receptor localizes to enteric neurons and endocrine cells expressing vasoactive peptides and mediates increased blood flow. Gastroenterology 130 (2006) 150-164
42. Guan X., Stoll B., Lu X., Tappenden K.A., Holst J.J., Hartmann B., and Burrin D.G. GLP-2-mediated up-regulation of intestinal blood flow and glucose uptake is nitric oxide-dependent in TPN-fed piglets 1. Gastroenterology 125 (2003) 136-147
43. Han V.K., D'Ercole A.J., and Lund P.K. Cellular localization of somatomedin (insulin-like growth factor) messenger RNA in the human fetus. Science 236 (1987) 193-197
44. Haramis A.P., Begthel H., van den Born M., van Es J., Jonkheer S., Offerhaus G.J., and Clevers H. De novo crypt formation and juvenile polyposis on BMP inhibition in mouse intestine. Science 303 (2004) 1684-1686
45. Hartmann B., Harr M.B., Jeppesen P.B., Wojdemann M., Deacon C.F., Mortensen P.B., and Holst J.J. In vivo and in vitro degradation of glucagon-like peptide-2 in humans. J. Clin. Endocrinol. Metab. 85 (2000) 2884-2888
46. He X.C., Yin T., Grindley J.C., Tian Q., Sato T., Tao W.A., Dirisina R., Porter-Westpfahl K.S., Hembree M., Johnson T., Wiedemann L.M., Barrett T.A., Hood L., Wu H., and Li L. PTEN-deficient intestinal stem cells initiate intestinal polyposis. Nat. Genet. 39 (2007) 189-198
47. He X.C., Zhang J., Tong W.G., Tawfik O., Ross J., Scoville D.H., Tian Q., Zeng X., He X., Wiedemann L.M., Mishina Y., and Li L. BMP signaling inhibits intestinal stem cell self-renewal through suppression of Wnt-beta-catenin signaling. Nat. Genet. 36 (2004) 1117-1121
48. Hirotani Y., Yamamoto K., Yanaihara C., Balaspiri L., Yanaihara N., and Kurokawa K. Distinctive effects of glicentin GLP-1 and GLP-2 on adaptive response to massive distal small intestine resection in rats. Ann. N.Y. Acad. Sci. 921 (2000) 460-463
49. Howarth G.S. Insulin-like growth factor-I and the gastrointestinal system: therapeutic indications and safety implications. J. Nutr. 133 (2003) 2109-2112
50. Iakoubov R., Izzo A., Yeung A., Whiteside C.I., and Brubaker P.L. Protein kinase Czeta is required for oleic acid-induced secretion of glucagon-like peptide-1 by intestinal endocrine L cells. Endocrinology 148 (2007) 1089-1098
51. Jeppesen P.B., Sanguinetti E.L., Buchman A., Howard L., Scolapio J.S., Ziegler T.R., Gregory J., Tappenden K.A., Holst J., and Mortensen P.B. Teduglutide (ALX-0600), a dipeptidyl peptidase IV resistant glucagon-like peptide 2 analogue, improves intestinal function in short bowel syndrome patients. Gut 54 (2005) 1224-1231
52. Kato Y., Yu D., and Schwartz M.Z. Glucagonlike peptide-2 enhances small intestinal absorptive function and mucosal mass in vivo. J. Pediatr. Surg. 34 (1999) 18-20 discussion 11-20
53. Kayahara T., Sawada M., Takaishi S., Fukui H., Seno H., Fukuzawa H., Suzuki K., Hiai H., Kageyama R., Okano H., and Chiba T. Candidate markers for stem and early progenitor cells, Musashi-1 and Hes1, are expressed in crypt base columnar cells of mouse small intestine. FEBS Lett. 535 (2003) 131-135
54. Kim K.A., Kakitani M., Zhao J., Oshima T., Tang T., Binnerts M., Liu Y., Boyle B., Park E., Emtage P., Funk W.D., and Tomizuka K. Mitogenic influence of human R-spondin1 on the intestinal epithelium. Science 309 (2005) 1256-1259
55. Kinzler K.W., and Vogelstein B. Lessons from hereditary colorectal cancer. Cell 87 (1996) 159-170
56. Koehler J.A., Yusta B., and Drucker D.J. The HeLa cell glucagon-like peptide-2 receptor is coupled to regulation of apoptosis and ERK1/2 activation through divergent signaling pathways. Mol. Endocrinol. 19 (2005) 459-473
57. Korinek V., Barker N., Moerer P., van Donselaar E., Huls G., Peters P.J., and Clevers H. Depletion of epithelial stem-cell compartments in the small intestine of mice lacking Tcf-4. Nat. Genet. 19 (1998) 379-383
58. L'Heureux M.C., and Brubaker P.L. Glucagon-like peptide-2 and common therapeutics in a murine model of ulcerative colitis. J. Pharmacol. Exp. Ther. 306 (2003) 347-354
59. Litvak D.A., Hellmich M.R., Evers B.M., Banker N.A., and Townsend Jr. C.M. Glucagon-like peptide 2 is a potent growth factor for small intestine and colon. J. Gastrointest. Surg. 2 (1998) 146-150
60. Lund P.K. Molecular basis of intestinal adaptation: the role of the insulin-like growth factor system. Ann. N.Y. Acad. Sci. 859 (1998) 18-36
61. Lund P.K., Moats-Staats B.M., Hynes M.A., Simmons J.G., Jansen M., D'Ercole A.J., and Van Wyk J.J. Somatomedin-C/insulin-like growth factor-I and insulin-like growth factor-II mRNAs in rat fetal and adult tissues. J. Biol. Chem. 261 (1986) 14539-14544
62. MacDonald R.S. The role of insulin-like growth factors in small intestinal cell growth and development. Horm. Metab. Res. 31 (1999) 103-113
63. Martin G.R., Wallace L.E., and Sigalet D.L. Glucagon-like peptide-2 induces intestinal adaptation in parenterally fed rats with short bowel syndrome. Am. J. Physiol. Gastrointest. Liver Physiol. 286 (2004) G964-G972
64. Moser A.R., Pitot H.C., and Dove W.F. A dominant mutation that predisposes to multiple intestinal neoplasia in the mouse. Science 247 (1990) 322-324
65. Muncan V., Sansom O.J., Tertoolen L., Phesse T.J., Begthel H., Sancho E., Cole A.M., Gregorieff A., de Alboran I.M., Clevers H., and Clarke A.R. Rapid loss of intestinal crypts upon conditional deletion of the Wnt/Tcf-4 target gene c-Myc. Mol. Cell Biol. 26 (2006) 8418-8426
66. Munkholm P., Langholz E., Davidsen M., and Binder V. Intestinal cancer risk and mortality in patients with Crohn's disease. Gastroenterology 105 (1993) 1716-1723
67. Munroe D.G., Gupta A.K., Kooshesh F., Vyas T.B., Rizkalla G., Wang H., Demchyshyn L., Yang Z.J., Kamboj R.K., Chen H., McCallum K., Sumner-Smith M., Drucker D.J., and Crivici A. Prototypic G protein-coupled receptor for the intestinotrophic factor glucagon-like peptide 2. Proc. Natl. Acad. Sci. U.S.A. 96 (1999) 1569-1573
68. Nachmias B., Ashhab Y., and Ben-Yehuda D. The inhibitor of apoptosis protein family (IAPs): an emerging therapeutic target in cancer. Semin. Cancer Biol. 14 (2004) 231-243
69. Nelson D.W., Sharp J.W., Brownfield M.S., Raybould H.E., and Ney D.M. Localization and activation of glucagon-like peptide-2 receptors on vagal afferents in the rat. Endocrinology 148 (2007) 1954-1962
70. Ney D.M., Huss D.J., Gillingham M.B., Kritsch K.R., Dahly E.M., Talamantez J.L., and Adamo M.L. Investigation of insulin-like growth factor (IGF)-I and insulin receptor binding and expression in jejunum of parenterally fed rats treated with IGF-I or growth hormone. Endocrinology 140 (1999) 4850-4860
71. Ohneda K., Ulshen M.H., Fuller C.R., D'Ercole A.J., and Lund P.K. Enhanced growth of small bowel in transgenic mice expressing human insulin-like growth factor I. Gastroenterology 112 (1997) 444-454
72. Orskov C., Hartmann B., Poulsen S.S., Thulesen J., Hare K.J., and Holst J.J. GLP-2 stimulates colonic growth via KGF, released by subepithelial myofibroblasts with GLP-2 receptors. Regul. Pept. 124 (2005) 105-112
73. Orskov C., Holst J.J., Knuhtsen S., Baldissera F.G., Poulsen S.S., and Nielsen O.V. Glucagon-like peptides GLP-1 and GLP-2, predicted products of the glucagon gene, are secreted separately from pig small intestine but not pancreas. Endocrinology 119 (1986) 1467-1475
74. Oshima M., Oshima H., Kitagawa K., Kobayashi M., Itakura C., and Taketo M. Loss of Apc heterozygosity and abnormal tissue building in nascent intestinal polyps in mice carrying a truncated Apc gene. Proc. Natl. Acad. Sci. U.S.A. 92 (1995) 4482-4486
75. Pete G., Fuller C.R., Oldham J.M., Smith D.R., D'Ercole A.J., Kahn C.R., and Lund P.K. Postnatal growth responses to insulin-like growth factor I in insulin receptor substrate-1-deficient mice. Endocrinology 140 (1999) 5478-5487
76. Pinto D., Gregorieff A., Begthel H., and Clevers H. Canonical Wnt signals are essential for homeostasis of the intestinal epithelium. Genes Dev. 17 (2003) 1709-1713
77. Playford M.P., Bicknell D., Bodmer W.F., and Macaulay V.M. Insulin-like growth factor 1 regulates the location, stability, and transcriptional activity of beta-catenin. Proc. Natl. Acad. Sci. U.S.A. 97 (2000) 12103-12108
78. Potten C.S. Stem cells in gastrointestinal epithelium: numbers, characteristics and death. Philos. Trans. R. Soc. Lond. B Biol. Sci. 353 (1998) 821-830
79. Potten C.S. Radiation, the ideal cytotoxic agent for studying the cell biology of tissues such as the small intestine. Radiat. Res. 161 (2004) 123-136
80. Potten C.S., Booth C., Tudor G.L., Booth D., Brady G., Hurley P., Ashton G., Clarke R., Sakakibara S., and Okano H. Identification of a putative intestinal stem cell and early lineage marker; musashi-1. Differentiation 71 (2003) 28-41
81. Powell S.M., Zilz N., Beazer-Barclay Y., Bryan T.M., Hamilton S.R., Thibodeau S.N., Vogelstein B., and Kinzler K.W. APC mutations occur early during colorectal tumorigenesis. Nature 359 (1992) 235-237
82. Prasad R., Alavi K., and Schwartz M.Z. Glucagonlike peptide-2 analogue enhances intestinal mucosal mass after ischemia and reperfusion. J Pediatr Surg 35 (2000) 357-359
83. Radtke F., and Clevers H. Self-renewal and cancer of the gut: two sides of a coin. Science 307 (2005) 1904-1909
84. Ramsanahie A., Duxbury M.S., Grikscheit T.C., Perez A., Rhoads D.B., Gardner-Thorpe J., Ogilvie J., Ashley S.W., Vacanti J.P., and Whang E.E. Effect of GLP-2 on mucosal morphology and SGLT1 expression in tissue-engineered neointestine. Am. J. Physiol. Gastrointest. Liver Physiol. 285 (2003) G1345-G1352
85. Rizvi A.Z., Hunter J.G., and Wong M.H. Gut-derived stem cells. Surgery 137 (2005) 585-590
86. Rocca A.S., and Brubaker P.L. Role of the vagus nerve in mediating proximal nutrient-induced glucagon-like peptide-1 secretion. Endocrinology 140 (1999) 1687-1694
87. Rothenberg M.E., Eilertson C.D., Klein K., Mackin R.B., and Noe B.D. Evidence for redundancy in propeptide/prohormone convertase activities in processing proglucagon: an antisense study. Mol. Endocrinol. 10 (1996) 331-341
88. Rouille Y., Martin S., and Steiner D.F. Differential processing of proglucagon by the subtilisin-like prohormone convertases PC2 and PC3 to generate either glucagon or glucagon-like peptide. J. Biol. Chem. 270 (1995) 26488-26496
89. Rouille Y., Westermark G., Martin S.K., and Steiner D.F. Proglucagon is processed to glucagon by prohormone convertase PC2 in alpha TC1-6 cells. Proc. Natl. Acad. Sci. U.S.A. 91 (1994) 3242-3246
90. Ryan J., and Costigan D.C. Determination of the histological distribution of insulin like growth factor 1 receptors in the rat gut. Gut 34 (1993) 1693-1697
91. Schmidt G.H., Winton D.J., and Ponder B.A. Development of the pattern of cell renewal in the crypt-villus unit of chimaeric mouse small intestine. Development 103 (1988) 785-790
92. Schneeman B.O. Gastrointestinal physiology and functions. Br. J Nutr. 88 Suppl. 2 (2002) S159-S161
93. Scott R.B., Kirk D., MacNaughton W.K., and Meddings J.B. GLP-2 augments the adaptive response to massive intestinal resection in rat. Am. J. Physiol. 275 (1998) G911-G921
94. Sheng H., Shao J., Townsend Jr. C.M., and Evers B.M. Phosphatidylinositol 3-kinase mediates proliferative signals in intestinal epithelial cells. Gut 52 (2003) 1472-1478
95. Shi M., Wei L.C., Cao R., and Chen L.W. Enhancement of nestin protein-immunoreactivity induced by ionizing radiation in the forebrain ependymal regions of rats. Neurosci. Res. 44 (2002) 475-481
96. Shin E.D., Estall J.L., Izzo A., Drucker D.J., and Brubaker P.L. Mucosal adaptation to enteral nutrients is dependent on the physiologic actions of glucagon-like peptide-2 in mice. Gastroenterology 128 (2005) 1340-1353
97. Sigalet D.L., and Martin G.R. Hormonal therapy for short bowel syndrome. J. Pediatr. Surg. 35 (2000) 360-363 discussion 364
98. Sigalet D.L., Wallace L.E., Holst J.J., Martin G.R., Kaji T., Tanaka H., and Sharkey K.A. Enteric neural pathways mediate the anti-inflammatory actions of glucagon-like peptide 2. Am. J. Physiol. Gastrointest. Liver Physiol. 293 (2007) G211-G221
99. Stappenbeck T.S., Wong M.H., Saam J.R., Mysorekar I.U., and Gordon J.I. Notes from some crypt watchers: regulation of renewal in the mouse intestinal epithelium. Curr. Opin. Cell. Biol. 10 (1998) 702-709
100. Stevens F.M., Flanagan R.W., O'Gorman D., and Buchanan K.D. Glucagonoma syndrome demonstrating giant duodenal villi. Gut 25 (1984) 784-791
101. Tahara H., Yasui W., Tahara E., Fujimoto J., Ito K., Tamai K., Nakayama J., Ishikawa F., Tahara E., and Ide T. Immuno-histochemical detection of human telomerase catalytic component, hTERT, in human colorectal tumor and non-tumor tissue sections. Oncogene 18 (1999) 1561-1567
102. Tavares W., Drucker D.J., and Brubaker P.L. Enzymatic- and renal-dependent catabolism of the intestinotropic hormone glucagon-like peptide-2 in rats. Am. J. Physiol. Endocrinol. Metab. 278 (2000) E134-E139
103. Taylor J.A., Bernabe K.Q., Guo J., and Warner B.W. Epidermal growth factor receptor-directed enterocyte proliferation does not induce Wnt pathway transcription. J. Pediatr. Surg. 42 (2007) 981-986
104. Thulesen J., Hartmann B., Hare K.J., Kissow H., Orskov C., Holst J.J., and Poulsen S.S. Glucagon-like peptide 2 (GLP-2) accelerates the growth of colonic neoplasms in mice. Gut 53 (2004) 1145-1150
105. Tian Q., Feetham M.C., Tao W.A., He X.C., Li L., Aebersold R., and Hood L. Proteomic analysis identifies that 14-3-3zeta interacts with beta-catenin and facilitates its activation by Akt. Proc. Natl. Acad. Sci. U.S.A. 101 (2004) 15370-15375
106. Tsai C.H., Hill M., Asa S.L., Brubaker P.L., and Drucker D.J. Intestinal growth-promoting properties of glucagon-like peptide-2 in mice. Am. J. Physiol. 273 (1997) E77-E84
107. Tsai C.H., Hill M., and Drucker D.J. Biological determinants of intestinotrophic properties of GLP-2 in vivo. Am. J. Physiol. 272 (1997) G662-G668
108. van de Wetering M., Sancho E., Verweij C., de Lau W., Oving I., Hurlstone A., van der Horn K., Batlle E., Coudreuse D., Haramis A.P., Tjon-Pon-Fong M., Moerer P., van den Born M., Soete G., Pals S., Eilers M., Medema R., and Clevers H. The beta-catenin/TCF-4 complex imposes a crypt progenitor phenotype on colorectal cancer cells. Cell 111 (2002) 241-250
109. van Es J.H., Jay P., Gregorieff A., van Gijn M.E., Jonkheer S., Hatzis P., Thiele A., van den Born M., Begthel H., Brabletz T., Taketo M.M., and Clevers H. Wnt signalling induces maturation of Paneth cells in intestinal crypts. Nat. Cell. Biol. 7 (2005) 381-386
110. Vanderwinden J.M., Gillard K., De Laet M.H., Messam C.A., and Schiffmann S.N. Distribution of the intermediate filament nestin in the muscularis propria of the human gastrointestinal tract. Cell Tissue Res. 309 (2002) 261-268
111. Wang Q., Wang X., Hernandez A., Hellmich M.R., Gatalica Z., and Evers B.M. Regulation of TRAIL expression by the phosphatidylinositol 3-kinase/Akt/GSK-3 pathway in human colon cancer cells. J. Biol. Chem. 277 (2002) 36602-36610
112. Wang Y., Wang L., Iordanov H., Swietlicki E.A., Zheng Q., Jiang S., Tang Y., Levin M.S., and Rubin D.C. Epimorphin(-/-) mice have increased intestinal growth, decreased susceptibility to dextran sodium sulfate colitis, and impaired spermatogenesis. J. Clin. Invest. 116 (2006) 1535-1546
113. Wielenga V.J., Smits R., Korinek V., Smit L., Kielman M., Fodde R., Clevers H., and Pals S.T. Expression of CD44 in Apc and Tcf mutant mice implies regulation by the WNT pathway. Am. J. Pathol. 154 (1999) 515-523
114. Williams K.L., Fuller C.R., Fagin J., and Lund P.K. Mesenchymal IGF-I overexpression: paracrine effects in the intestine, distinct from endocrine actions. Am. J. Physiol. Gastrointest. Liver Physiol. 283 (2002) G875-G885
115. Winesett D.E., Ulshen M.H., Hoyt E.C., Mohapatra N.K., Fuller C.R., and Lund P.K. Regulation and localization of the insulin-like growth factor system in small bowel during altered nutrient status. Am. J. Physiol. 268 (1995) G631-G640
116. Wu A., Chen J., and Baserga R. Nuclear insulin receptor substrate-1 activates promoters of cell cycle progression genes. Oncogene 27 (2008) 397-403
117. Xiao Q., Boushey R.P., Drucker D.J., and Brubaker P.L. Secretion of the intestinotropic hormone glucagon-like peptide 2 is differentially regulated by nutrients in humans. Gastroenterology 117 (1999) 99-105
118. Yusta B., Boushey R.P., and Drucker D.J. The glucagon-like peptide-2 receptor mediates direct inhibition of cellular apoptosis via a cAMP-dependent protein kinase-independent pathway. J. Biol. Chem. 275 (2000) 35345-35352
119. Yusta B., Huang L., Munroe D., Wolff G., Fantaske R., Sharma S., Demchyshyn L., Asa S.L., and Drucker D.J. Enteroendocrine localization of GLP-2 receptor expression in humans and rodents. Gastroenterology 119 (2000) 744-755
120. Yusta B., Somwar R., Wang F., Munroe D., Grinstein S., Klip A., and Drucker D.J. Identification of glucagon-like peptide-2 (GLP-2)-activated signaling pathways in baby hamster kidney fibroblasts expressing the rat GLP-2 receptor. J Biol Chem 274 (1999) 30459-30467